T/O PRICE, page-7

Typical valuations of SAAS (Software as a service) recurring revenue models with high retention "stickness" are commonly in the 20-30 times earnings + alfa (future growth potential)

Given RAP's unique patented AI software & position way ahead of any competition I would say once we have FDA approval i.e (we will then have Australia, TGA, Europe CE Mark and USA /global US FDA approval for infants + we get a few deals (Sanofi and perhaps Ping An Health and others under our belt with revenue coming in I would anticipate a rapidly climbing share price.

Ultimately I see opportunist short term Take over price in the A$2-3 range however I think this would significantly undervalue the the company. All going good I can easily see a take over price 5 years out could IMHO be in the A$ 7.50 - A$10 range.

However first things first - things have to go right the current FDA approval is VERY important - we have the best people (Experian) working on it over 99% success rate, the US is moving more rapidly than most markets in Telehealth and FDA while a US approval only is taken in many markets as a Global standard.

Of course there are still "gaps" for management to fill i.e
Adult Respiratory TGA, CE approval and US adult testing & FDA approval (Note If the current FDA approval infant respiratory is successful it should hopefully make adult approval easier and hopefully faster)
Sleep Apnea TGA & CE Approval and US Sleep Apnea Testing and Approval

However great news due in the next 1-3 months FDA Infant Respiratory Approval and First significant revenue contracts with hopefully Sanofi and perhaps Ping An should see a significant a RAP share price re-rate. At the moment we are just meandering and sometimes getting lost in the foothills if the above comes to past hang on to your hats as we will really start climbing the mountain.
GLTA Thai